MASSACHUSETTS GENERAL HOSPITAL

Funding Organization

Awards Grant

  • A Phase II of Rituximab in Myasthenia Gravis (NN 103)
  • A Phase ll of Rituximab in Myasthenia Gravis (NN 103)
  • A Placebo-Controlled, Crossover Study of FanaptĀ® (iloperidone) Augmentation of SSRIs for Residual Anger and Irritability in Major Depressive Disorder
  • An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)
  • Assay of Inflammatory Cytokines, High Sensitivity C-Reactive Protein, Leptin, and Insulin in Plasma Samples of Outpatient Participants in L-Methylfolate (DeplinĀ®) TRD-I and TRD-II Trials
  • Ciliogenesis in Epithelial Injury
  • Clinical and MRI Features of NMO Spectrum Disorders in Children
  • Coenzyme Q10 (CoQ) in Huntington's Disease (2CARE)
  • Comparative Effectiveness Trial of Early Integrated Telehealth Versus In-Person Palliative Care for Patients with Advanced Lunch Cancer (Short Name: REACH PC)
  • Comparative Effectiveness of a Second Generation Antipsychotic Mood Stabilizer and a Classic Mood Stabilizer for Bipolar Disorder
  • Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
  • Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
  • Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
  • Development of Optical Coherence Tomography for Measures of Mucociliary Clearance
  • Development of Optical Coherence Tomography for Measures of Mucociliary Clearance (MCC)
  • Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)
  • Falling off the HIV Treatment Cascade Cliff: Understanding Postpartum Attrition to HIV Care
  • Metabolic Predictors of Stroke in REGARDS
  • Modeling X-Linked Dystonia Parkinsonism Using BAC Transgenesis
  • Molecular Etiology of Early Onset Torsin Dystonia
  • Molecular Etiology of Early Onset Torsion Dystonia
  • Molecular Markers of Early Cardiometabolic Health Transitions in the CARDIA Study
  • NN106 Cytochrome C Oxidase Activity In Newly Diagnosed Glioblastoma Multiforme (GBM)
  • Patient-family Views on Pediatric MS Research, Needs, Outcomes, and Methods
  • Phase 3 Trial of Inosine for Parkinson's Disease CCC
  • Proteomic, Genomic, and Longitudinal Paths to Ovarian Cancer Biomarker Discovery
  • Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
  • Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332) and ACTG A6333s The Mechanistic Substudy of REPRIEVE
  • Rapidly-Acting Treatments for Treatment-Resistance Depression
  • SPRINT-MS: A Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects with Progressive Multiple Sclerosis (NN 102)
  • SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
  • Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia
  • Topiramate as a Disease Altering Therapy for Cryptogenic Sensory Peripheral Neuropalhy (CSPN)